Frimley

FRIMLEY, England, January 21, 2011 - Siemens' employees are taking up the challenge of rowing to raise vital funds for The Stroke Association.

FRIMLEY, England, January 13, 2011 - Novartis Pharmaceuticals UK Ltd today announced that Lucentis(R) (ranibizumab) is being launched in the UK for the treatment of visual impairment due to diabetes, specifically diabetic macular oedema (DMO).

FRIMLEY, England, June 5, 2010 - - Data show zoledronic acid, a bisphosphonate, provided significant clinical anticancer benefit and significantly reduced risk of skeletal- related events(1,2) - Overall survival advantage observed with zoledronic acid plus chemotherapy versus oral clodronate plus chemotherapy is independent of skeletal-related event benefit(1) - Results from a separate five-year follow-up study of hormone receptor-positive premenopausal early breast cancer patients showed significant improvement in progression-free survival with zoledronic acid in this patient population(2) New data to be presented tomorrow at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, from the Myeloma IX study, show that zoledronic acid plus first-line chemotherapy significantly improved overall survival for newly diagnosed multiple myeloma patients by 16% (P=0.0118) and progression-free survival by 12%, (P=0.0179) compared to oral clodronate plus first-line chemotherapy(1).

FRIMLEY, England, June 1, 2010 - - Just for UK media, not for Ireland - This release is intended for consumer media - Add-On Omalizumab Reduces the Rate of Asthma Attacks in Children Aged 6 to 11 Years With Severe Persistent Allergic Asthma Whose Symptoms Remain Uncontrolled Despite Best Available Current Therapies[2] - Today's Decision Made Despite Pivotal Study Showing Omalizumab Halves Asthma Attacks at One Year With a Good Overall Safety and Tolerability Profile in Children Aged 6 to 11 Years [3,4] Novartis is disappointed that the National Institute for Health and Clinical Excellence (NICE) has decided against recommending omalizumab for children aged 6 to 11 years with severe, persistent allergic asthma in England and Wales because it does not consider it to be a cost-effective use of NHS resources1.

FRIMLEY, England, April 13, 2010 - Developed for UK consumer and medical journalists Not intended for media in Republic of Ireland New Data Presented at the AAN Show That Treatment With Fingolimod: - Improves Self-Reported Ability to Perform Daily Activities for People With Multiple Sclerosis (MS) - Reduces Severity of Relapses, as Compared to Interferon Beta -1a, With Significantly Less Need for Steroid Intervention and Hospitalisation - Benefits Patients Switched From Interferon Beta -1a to Fingolimod, With Significantly Reduced Relapse Rates and Improved Brain Lesion Measures - Reduces Relapses by 62% in Newly Treated Patients The recent publication of two pivotal studies (FREEDOMS and TRANSFORMS) in the New England Journal of Medicine (NEJM) confirmed that daily multiple sclerosis pill, fingolimod, was twice as effective as a commonly used injection (interferon Beta -1a) and placebo for the treatment of relapsing-remitting multiple sclerosis (RRMS) - the most common form of the disease.(1,2,3) New data presented this week at the 62nd annual meeting of the American Academy of Neurology (AAN) adds to the growing body of evidence to support fingolimod, showing additional benefits for patients.